Promising Results in Clinical Study for Acne Drug Candidate
SkinInc.com
Novan Therapeutics,announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers. This study in combination with Novan’s earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne.
read all at
Ponatinib
Ariad begins Phase 2 trial of Iclusig to treat GI tumors
Boston Business Journal (blog)
Ariad Pharmaceuticals, Inc. has launched a Phase 2 trial to test its approved leukemia drug Iclusig as a potential treatment for gastrointestinal stromal tumors (GIST).
The Cambridge, Mass-based company’s drug was approved by the U.S. Food and Drug Administration in December 2012. It’s approved to treat certain patients chronic myeloid leukemia (CML) that is resistant or intolerant to other drugs and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
read all at
http://www.bizjournals.com/boston/blog/bioflash/2013/06/ariad-trial-cancer-drug.html
An efficient, telescopic, and scalable process for an antihypertensive drug substance, valsartan with an overall yield of 58%, and 
99.9% purity is described. A simple, and safe process is developed for the recovery of tributyltin chloride from the tributyltin hydroxide, byproduct formed in the tetrazole ring construction, and reused in the synthesis of valsartan.
Dr. Reddy’s Laboratories
Org. Process Res. Dev., 2012, 16 (4), pp 682–686
Colorado-based Clovis said in a statement today. The drug, CO-1686, is in the first of three phases of testing typically required before U.S. regulatory approval.
http://www.businessweek.com/news/2013-06-03/clovis-oncology-shares-almost-double-on-ovarian-drug-trial-data
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3Rx treatment resulted in partial responses that were durable and prolonged in two out of three patients with diffuse large B-cell lymphoma (DLBCL) who were refractory to prior chemotherapy treatments. Isis and AstraZeneca are currently evaluating ISIS-STAT3Rx, in two clinical studies in patients with advanced lymphoma and metastatic liver cancer.
Read more here:
http://www.heraldonline.com/2013/06/03/4913337/isis-pharmaceuticals-reports-encouraging.html
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Two Array Invented MEK Inhibitors Showcased At ASCO
Sacramento Bee
AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.
http://www.sacbee.com/2013/06/03/5466446/two-array-invented-mek-inhibitors.html
Two Array BioPharma-invented MEK inhibitors, selumetinib and MEK162, were showcased at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.
read all at
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
AsianScientist (Jun. 3, 2013) – By Sunanda Creagh – Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease, a condition commonly affecting small children that can lead to deadly infection of the brain and spinal cord membranes.
read all at
http://www.asianscientist.com/health-medicine/world-hand-foot-mouth-vaccine-developed-2013/
